The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies

被引：8
作者：
Gao, Rili [1 ]
Zhang, Yikai [1 ,2 ]
Zeng, Chengwu [1 ]
Li, Yangqiu [1 ]
机构：
[1] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou 510632, Peoples R China
[2] Tianhe Nuoya Bioengn Co Ltd, Guangzhou 510663, Peoples R China
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2022年 / 921卷
基金：
中国博士后科学基金; 中国国家自然科学基金;
关键词：
Nuclear factor of activated T cells; Hematological malignancies; Target therapy; T cells immunity; T-CELL-ACTIVATION; MYELOID-LEUKEMIA AML; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; LYMPHOCYTE-ACTIVATION; DOWN-REGULATION; CYCLOSPORINE-A; KAPPA-B; CALCINEURIN; EXPRESSION;
D O I：
10.1016/j.ejphar.2022.174889
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The nuclear factor of activated T cells (NFAT) family is well known for the survival of hemopoietic cells and plays an important role in the immune response. In recent decades, NFAT alteration was discovered in hematological malignancies, suggesting that targeted NFAT therapy may be a promising strategy for the treatment of hematological malignancies. In this review, we present an overview of the NFAT signaling pathway in lymphocytes as well as aberrant NFAT in hematological malignancies. Moreover, therapeutically targeting NFAT in hematological malignancies is also discussed in this review.
引用
收藏
页数：8
相关论文
共 81 条
[1]   Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas [J].
Abate, Francesco ;
da Silva-Almeida, Ana C. ;
Zairis, Sakellarios ;
Robles-Valero, Javier ;
Couronne, Lucile ;
Khiabanian, Hossein ;
Quinn, S. Aidan ;
Kim, Mi-Yeon ;
Laginestra, Maria Antonella ;
Kim, Christine ;
Fiore, Danilo ;
Bhagat, Govind ;
Piris, Miguel Angel ;
Campo, Elias ;
Lossos, Izidore S. ;
Bernard, Olivier A. ;
Inghirami, Giorgio ;
Pileri, Stefano ;
Bustelo, Xose R. ;
Rabadan, Raul ;
Ferrando, Adolfo A. ;
Palomero, Teresa .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (04) :764-769
[2]   Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine [J].
Advani, Ranjana ;
Horwitz, Steven ;
Zelenetz, Andrew ;
Horning, Sandra J. .
LEUKEMIA & LYMPHOMA, 2007, 48 (03) :521-525
[3]   B Cell receptor directs the activation of NFAT and NF-κB via distinct molecular mechanisms [J].
Antony, P ;
Petro, JB ;
Carlesso, G ;
Shinners, NP ;
Lowe, J ;
Khan, WN .
EXPERIMENTAL CELL RESEARCH, 2003, 291 (01) :11-24
[4]   Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A [J].
Aramburu, J ;
Yaffe, MB ;
López-Rodríguez, C ;
Cantley, LC ;
Hogan, PG ;
Rao, A .
SCIENCE, 1999, 285 (5436) :2129-2133
[5]   Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy [J].
Bendickova, Kamila ;
Tidu, Federico ;
Fric, Jan .
EMBO MOLECULAR MEDICINE, 2017, 9 (08) :990-999
[6]   The Importance of Cooperation: Partnerless NFAT Induces T Cell Exhaustion [J].
Bengsch, Bertram ;
Wherry, E. John .
IMMUNITY, 2015, 42 (02) :203-205
[7]   Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma [J].
Bucher, Philip ;
Erdmann, Tabea ;
Grondona, Paula ;
Xu, Wendan ;
Schmitt, Anja ;
Schurch, Christoph ;
Zapukhlyak, Myroslav ;
Schoenfeld, Caroline ;
Serfling, Edgar ;
Kramer, Daniela ;
Grau, Michael ;
Klener, Pavel ;
Lengerke, Claudia ;
Schulze-Osthoff, Klaus ;
Lenz, Georg ;
Hailfinger, Stephan .
BLOOD, 2020, 135 (02) :121-132
[8]  
Cabanas Helene, 2018, Oncotarget, V9, P26309, DOI 10.18632/oncotarget.25241
[9]   NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia [J].
Catherinet, Claire ;
Passaro, Diana ;
Gachet, Stephanie ;
Medyouf, Hind ;
Reynaud, Anne ;
Lasgi, Charlene ;
Ghysdael, Jacques ;
Tran Quang, Christine .
PLOS ONE, 2021, 16 (07)
[10]   Treatment of myelodysplastic syndrome with cyclosporin A [J].
Chen, Shuchang ;
Jiang, Bin ;
Da, Wanming ;
Gong, Ming ;
Guana, Mei .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (01) :11-17
123456789